Tripos Discovery Research Enters Agreement with CombinatoRx to Optimize Novel Compounds
News Aug 29, 2007
Tripos Discovery Research Limited (TDR), a wholly owned subsidiary of Commonwealth Biotechnologies, Inc. has announced that it has entered into a service agreement with CombinatoRx, Incorporated (CombinatoRx).
Using its combination “High Throughput Screening” technology, cHTS™, CombinatoRx has identified synergistic combinations with utility in key indications which TDR will optimize utilizing its expertise in computational and medicinal chemistry and partner ADME services.
Dr. Mark Warne, Managing Director of TDR, stated, “We are delighted to be entering into this new and exciting agreement with CombinatoRx. Following TDR’s recent acquisition by CBI, this agreement serves as further confirmation that we remain focused on providing integrated drug discovery services to the pharmaceutical and biotech community, working closely with our clients throughout the drug discovery process.”
Modified Form of Botox Could Replace Opioids as Treatment for Chronic PainNews
A modified form of botulinum toxin gives long-lasting pain relief in mice without adverse effects and, in time, could replace opioid drugs as a safe and effective way of treating chronic pain, according to new research.READ MORE
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
Tackling Cancer at Ground Zero: Designer Molecule Inhibits Protein TargetNews
A new molecule designed by University of Adelaide researchers shows great promise for future treatment of many cancers. The new molecule successfully targets a protein that plays a major role in the growth of most cancers.READ MORE
5th edition of the International Conference Clinical Oncology and Molecular Diagnostics
Jun 17 - Jun 18, 2019